$10.47 Million in Sales Expected for Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) This Quarter

Wall Street brokerages expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRSGet Rating) to post sales of $10.47 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $17.70 million and the lowest estimate coming in at $3.24 million. Pieris Pharmaceuticals reported sales of $3.29 million during the same quarter last year, which indicates a positive year-over-year growth rate of 218.2%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year sales of $45.71 million for the current year, with estimates ranging from $20.71 million to $70.70 million. For the next year, analysts anticipate that the firm will post sales of $47.01 million, with estimates ranging from $9.32 million to $84.70 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRSGet Rating) last posted its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 92.04% and a negative net margin of 175.99%. During the same period last year, the company posted ($0.07) EPS.

A number of research analysts have weighed in on the company. StockNews.com initiated coverage on Pieris Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Tuesday, May 17th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC increased its holdings in Pieris Pharmaceuticals by 55.6% in the 1st quarter. Hsbc Holdings PLC now owns 20,556 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 7,343 shares in the last quarter. Royal Bank of Canada increased its holdings in Pieris Pharmaceuticals by 226.0% in the 2nd quarter. Royal Bank of Canada now owns 12,975 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 8,995 shares in the last quarter. Cetera Advisors LLC acquired a new stake in Pieris Pharmaceuticals in the 3rd quarter valued at $52,000. Oppenheimer & Co. Inc. acquired a new stake in Pieris Pharmaceuticals in the 1st quarter valued at $32,000. Finally, Blair William & Co. IL increased its holdings in Pieris Pharmaceuticals by 9.1% in the 1st quarter. Blair William & Co. IL now owns 128,745 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 10,760 shares in the last quarter. Hedge funds and other institutional investors own 65.30% of the company’s stock.

Shares of Pieris Pharmaceuticals stock opened at $1.75 on Tuesday. Pieris Pharmaceuticals has a fifty-two week low of $1.61 and a fifty-two week high of $6.15. The firm has a market cap of $129.68 million, a PE ratio of -2.54 and a beta of 1.19. The business’s fifty day moving average is $2.77 and its two-hundred day moving average is $3.20.

Pieris Pharmaceuticals Company Profile (Get Rating)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.

Read More

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.